BOSTON SCIENTIFIC CORP
NYSE: BSX (Boston Scientific Corporation)
Last update: 3 hours ago93.55
1.04 (1.12%)
| Previous Close | 92.51 |
| Open | 92.15 |
| Volume | 12,253,107 |
| Avg. Volume (3M) | 9,579,611 |
| Market Cap | 138,736,500,736 |
| Price / Earnings (TTM) | 50.03 |
| Price / Earnings (Forward) | 26.32 |
| Price / Sales | 7.04 |
| Price / Book | 5.79 |
| 52 Weeks Range | |
| Earnings Date | 4 Feb 2026 |
| Profit Margin | 11.58% |
| Operating Margin (TTM) | 20.09% |
| Diluted EPS (TTM) | 1.37 |
| Quarterly Revenue Growth (YOY) | 20.90% |
| Quarterly Earnings Growth (YOY) | 36.20% |
| Total Debt/Equity (MRQ) | 52.16% |
| Current Ratio (MRQ) | 1.45 |
| Operating Cash Flow (TTM) | 3.81 B |
| Levered Free Cash Flow (TTM) | 2.32 B |
| Return on Assets (TTM) | 5.28% |
| Return on Equity (TTM) | 9.50% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | Boston Scientific Corporation | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | 4.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | 1.50 |
|
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Large Core |
| % Held by Insiders | 0.18% |
| % Held by Institutions | 93.22% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Capital World Investors | 30 Sep 2025 | 26,648,948 |
| Bollard Group Llc | 30 Sep 2025 | 19,733,573 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 132.00 (BTIG, 41.10%) | Buy |
| Median | 130.00 (38.96%) | |
| Low | 100.00 (Oppenheimer, 6.90%) | Buy |
| Average | 122.60 (31.05%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 94.00 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Oppenheimer | 16 Jan 2026 | 100.00 (6.89%) | Buy | 88.07 |
| Truist Securities | 18 Dec 2025 | 120.00 (28.27%) | Buy | 96.11 |
| Canaccord Genuity | 17 Dec 2025 | 131.00 (40.03%) | Buy | 94.48 |
| RBC Capital | 17 Dec 2025 | 130.00 (38.96%) | Buy | 94.48 |
| BTIG | 21 Nov 2025 | 132.00 (41.10%) | Buy | 96.88 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 15 Jan 2026 | Announcement | Boston Scientific announces agreement to acquire Penumbra, Inc. |
| 12 Jan 2026 | Announcement | Boston Scientific Announces Agreement to Acquire Valencia Technologies Corporation |
| 02 Jan 2026 | Announcement | Boston Scientific announces participation in the J.P. Morgan Healthcare Conference and conference call discussing fourth quarter and full year 2025 results |
| 03 Nov 2025 | Announcement | Boston Scientific announces upcoming investor conference schedule |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |